Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis

BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt. METHODS: In this systematic review, phase 3 randomized controlled trials investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Shang‐Hsuan, Lin, Ching‐Hung, Chen, I‐Chun, Shen, Ying‐Chun, Chang, Dwan‐Ying, Chen, Tom Wei‐Wu, Huang, Shu‐Min, Hu, Fu‐Chang, Lu, Yen‐Shen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587960/
https://www.ncbi.nlm.nih.gov/pubmed/37737544
http://dx.doi.org/10.1002/cam4.6563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587960/
https://www.ncbi.nlm.nih.gov/pubmed/37737544
http://dx.doi.org/10.1002/cam4.6563

Ejemplares similares